This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Navidea Biopharmaceuticals Announces The Presentation Of Lymphoseek® Data At Upcoming Scientific Meetings In October

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that data from its Lymphoseek studies in breast cancer and melanoma are being presented during the month of October at the American Association of Pharmaceutical Scientists meeting in Chicago, IL, the European Association of Nuclear Medicine conference in Milan, Italy and the American Society for Radiation Oncology meeting in Boston, MA. Details of the presentations and posters are listed below.

Conference:  

American Association of Pharmaceutical Scientists

Date: October 14-18, 2012
Location: Chicago, IL
 
Poster Title 1:

The Effect of Post-Injection Time Interval of Tc 99m Tilmanocept Injection to In Vivo Probing on Nodal Concordance Rates Relative to Vital Blue Dye in Melanoma and Breast Cancer Patients Undergoing Intraoperative Lymphatic Mapping

Author: Frederick Cope, PhD, Navidea Biopharmaceuticals
Session, Date: Poster Sessions
 
Poster Title 2:

Sensitivities and False Negative Rates of Tc 99m Tilmanocept and Vital Blue Dye By Time Interval of Tc 99m Tilmanocept Injection to In Vivo Probing in Melanoma and Breast Cancer Patients Undergoing Intraoperative Lymphatic Mapping

Author: Wendy L. Metz, PhD, Navidea Biopharmaceuticals
Session, Date: Poster Sessions
 
Conference:

European Association of Nuclear Medicine

Date: October 27-31, 2012
Location: Milan, Italy
 
Presentation Title 1:

Phase 3 Trials Evaluating Biotargeted (CD206) Tc 99m Tilmanocept Against Vital Blue Dye (VBD) in the Detection of Lymph Nodes (LNs) in Breast Cancer (BC) Patients

Author: Frederick Cope, PhD, Navidea Biopharmaceuticals
Session, Date: Oncology Clinical Science: Sentinel Lymph Node 2 Session
Sunday, October 28, 2012
 
Presentation Title 2:

Clinical Performance of Tc 99m Tilmanocept Versus Vital Blue Dye (VBD) in the Detection of Lymph Nodes (LNs) in Melanoma Patients

Author: Frederick Cope, PhD, Navidea Biopharmaceuticals
Session, Date: Oncology Clinical Science: Sentinel Lymph Node 1 Session
Sunday, October 28, 2012
 
Conference:

American Society for Radiation Oncology (ASTRO)

Date: October 28-31, 2012
Location: Boston, MA
 
Poster Title:

Exploitation Targeting Of The CD206 Receptor In Lymph Node-Resident Reticuloendothelial Cells With A Novel Synthetic 99mTc-ligand (Tilmanocept) Significantly Enhances Localization In Contrast To 99mTc-Colloid: A New Meta-analysis

Author: Frederick Cope, PhD, Navidea Biopharmaceuticals
Session, Date: Poster Sessions

About Lymphoseek ®

Lymphoseek ® (technetium Tc 99m tilmanocept) Injection is a novel, receptor-targeted, small-molecule, investigational radiopharmaceutical used in lymphatic mapping procedures that are performed to help stage breast cancer and melanoma. Lymphoseek is designed to identify the lymph nodes that drain from a primary tumor, which have the highest probability of harboring cancer, in patients with breast cancer or melanoma.

Lymphatic mapping is a procedure in which lymph nodes that may contain tumor metastases are identified and biopsied to determine if cancer has spread beyond the primary tumor. Accurate staging of cancer is critical, as it guides therapy decisions and determines patient prognosis and risk of recurrence. According to the American Cancer Society, approximately 229,000 new cases of breast cancer and 76,000 new cases of melanoma are expected to be diagnosed in the United States in 2012.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,890.50 -85.81 -0.48%
S&P 500 2,079.18 -7.06 -0.34%
NASDAQ 4,928.8250 -18.6160 -0.38%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs